Brief: Biophytis: Last Patient Completes Final Visit In SARA-INT
16/12/2020 07:04
Dec 16 (Reuters) - Biophytis SA ALBPS.PA :
* LAST PATIENT COMPLETES FINAL VISIT IN SARA-INT
* SARA-INT IS PHASE 2 CLINICAL TRIAL EVALUATING THE EFFICACY
OF
SARCONEOS (BIO101) IN THE TREATMENT OF SARCOPENIA
* BIOPHYTIS EXPECTS TO REPORT TOP-LINE DATA FROM THIS
SARA-INT,
PHASE 2 CLINICAL TRIAL, IN Q2 2021
Source text: https://bit.ly/387q3hP
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon